Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2

Neuro-Oncology

Volumn 10, Issue 6, 2008, Pages 981-994

  Anderton, Jennifer A ^a   Lindsey, Janet C ^a   Lusher, Meryl E ^a   Gilbertson, Richard J ^b   Bailey, Simon ^a   Ellison, David W ^b   Clifford, Steven C ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

COL1A2; Desmoplasia; Epigenetics; Hyper methylation; Medulloblastoma

Indexed keywords

BISULFITE; DNA METHYLTRANSFERASE INHIBITOR; ALPHA 2(I) COLLAGEN; COLLAGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BRAIN TUMOR; CARCINOGENESIS; CEREBELLUM; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COL1A2 GENE; CONTROLLED STUDY; CPG ISLAND; DEREGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INFANT; MALE; MEDULLOBLASTOMA; METHYLATION; MICROARRAY ANALYSIS; PATHOGENESIS; PRIMARY TUMOR; PROGNOSIS; SEQUENCE ANALYSIS; TUMOR GENE; AGED; CEREBELLUM TUMOR; DNA METHYLATION; DNA MICROARRAY; FETUS; GENE SILENCING; GENETICS; HETEROZYGOSITY LOSS; MIDDLE AGED; NEWBORN; NUCLEOTIDE SEQUENCE; PATHOLOGY; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

AGED; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; CHILD, PRESCHOOL; COLLAGEN; CPG ISLANDS; DNA METHYLATION; FEMALE; FETUS; GENE SILENCING; HUMANS; INFANT, NEWBORN; LOSS OF HETEROZYGOSITY; MALE; MEDULLOBLASTOMA; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 57149120670     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-048     Document Type: Article

References (43)

1. Ellison DW, Clifford SC, Gajjar A, Gilbertson RJ. What's new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol. 2003;7:53-66.
2. Ellison DW, Clifford SC, Giangaspero F. Medulloblastoma. In: McLen-don RE, Rosenblum MK, Bigner DD, eds. Russell and Rubenstein's Pathology of Tumours of the Nervous System, 7th ed. London: Hodder Arnold; 2006:247-264.
3. Ellison DW, Onilude OE, Lindsey JC, et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol. 2005;23:7951-7957.
4. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medullo-blastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006;24:1924-1931.
5. McManamy CS, Lamont JM, Taylor RE, et al. Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. J Neuropathol Exp Neurol. 2003;62:627-632.
6. McManamy CS, Pears J, Weston CL, et al. Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior. Brain Pathol. 2007;17:151-164.
7. Clifford SC, Lusher ME, Lindsey JC, et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular subgroup of medulloblastomas associated with a favorable prognosis. Cell Cycle. 2006;5:2666-2670.
8. Fruhwald MC, O'Dorisio MS, Dai Z, et al. Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas - implications for tumor biology and potential clinical utility. Oncogene. 2001;20:5033-5042.
9. Lindsey JC, Anderton JA, Lusher ME, Clifford SC. Epigenetic events in medulloblastoma development. Neurosurg Focus. 2005;19:E10.
10. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet. 2002;31:141-149.
11. Yan PS, Chen CM, Shi H, et al. Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res. 2001;61:8375-8380.
12. Yamashita K, Upadhyay S, Osada M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell. 2002;2:485-495.
13. Wei SH, Balch C, Paik HH, et al. Prognostic DNA methylation bio-markers in ovarian cancer. Clin Cancer Res. 2006;12:2788-2794.
14. Waha A, Koch A, Hartmann W, et al. SGNE1/7B2 is epigenetically altered and transcriptionally downregulated in human medulloblasto-mas. Oncogene. 2007;26:5662-5668.
15. Vibhakar R, Foltz G, Yoon JG, et al. Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma. Neuro-Oncology. 2007;9:135-144.
16. Lusher ME, Lindsey JC, Latif F, Pearson AD, Ellison DW, Clifford SC. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. Cancer Res. 2002;62:5906-5911.
17. Lindsey JC, Lusher ME, Anderton JA, Gilbertson RJ, Ellison DW, Clifford SC. Epigenetic deregulation of multiple S100 gene family members by differential hypomethylation and hypermethylation events in medulloblastoma. Br J Cancer. 2007;97:267-274.
18. Rehman I, Cross SS, Azzouzi AR, et al. S100A6 (calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors. Br J Cancer. 2004;91:739-744.
19. Suzuki H, Itoh F, Toyota M, et al. Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. Int J Cancer. 1999;83:309-313.
20. Lindsey JC, Lusher ME, Anderton JA, et al. Identification of tumour-specific epigenetic events in medulloblastoma development by hyper-methylation profiling. Carcinogenesis. 2004;25:661-668.
21. Clifford SC, Cockman ME, Smallwood AC, et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet. 2001;10:1029-1038.
22. Sengupta PK, Smith EM, Kim K, Murnane MJ, Smith BD. DNA hyper-methylation near the transcription start site of collagen alpha2(I) gene occurs in both cancer cell lines and primary colorectal cancers. Cancer Res. 2003;63:1789-1797.
23. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S. Silencing of the E-cadherin invasion-suppressor gene by CpG methy-lation in human carcinomas. Proc Natl Acad Sci U S A. 1995;92:7416-7419.
24. Syed N, Smith P, Sullivan A, et al. Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood. 2006;107:250-256.
25. Muthusamy V, Duraisamy S, Bradbury CM, et al. Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 2006;66:11187-11193.
26. Ebinger M, Senf L, Wachowski O, Scheurlen W. Promoter methylation pattern of caspase-8, P16INK4A, MGMT, TIMP-3, and E-cadherin in medulloblastoma. Pathol Oncol Res. 2004;10:17-21.
27. Curradi M, Izzo A, Badaracco G, Landsberger N. Molecular mechanisms of gene silencing mediated by DNA methylation. Mol Cell Biol. 2002;22:3157-3173.
28. Antequera F, Boyes J, Bird A. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell. 1990;62:503-514.
29. Heard E, Clerc P, Avner P. X-chromosome inactivation in mammals. Annu Rev Genet. 1997;31:571-610.
30. Ehrbrecht A, Muller U, Wolter M, et al. Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J Pathol. 2006;208:554-563.
31. Reardon DA, Michalkiewicz E, Boyett JM, et al. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res. 1997;57:4042-4047.
32. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci. 2003;4:1002-1012.
33. Muhlisch J, Bajanowski T, Rickert CH, et al. Frequent but borderline methylation of p16 (INK4a) and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses. J Neurooncol. 2007;83:17-29.
34. Liang Y, Jansen M, Aronow B, Geiger H, Van Zant G. The quantitative trait gene latexin influences the size of the hematopoietic stem cell population in mice. Nat Genet. 2007;39:178-188.
35. Miyasaka N, Hatanaka Y, Jin M, Arimatsu Y. Genomic organization and regulatory elements of the rat latexin gene, which is expressed in a cell type-specific manner in both central and peripheral nervous systems. Brain Res. 1999;69:62-72.
36. Strathdee G, Sim A, Brown R. Control of gene expression by CpG island methylation in normal cells. Biochem Soc Trans. 2004;32:913-915.
37. Kalifa C, Grill J. The therapy of infantile malignant brain tumors: current status? J Neurooncol. 2005;75:279-285.
38. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. New Engl J Med. 2005;352:978-986.
39. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev. 2006;6:392-401.
40. Chiba T, Yokosuka O, Fukai K, et al. Identification and investigation of methylated genes in hepatoma. Eur J Cancer. 2005;41:1185-1194.
41. Travers H, French NS, Norton JD. Suppression of tumorigenicity in Ras-transformed fibroblasts by alpha 2(I) collagen. Cell Growth Differ. 1996;7:1353-1360.
42. Andreu T, Beckers T, Thoenes E, Hilgard P, von Melchner H. Gene trapping identifies inhibitors of oncogenic transformation. The tissue inhibitor of metalloproteinases-3 (TIMP3) and collagen type I alpha2 (COL1A2) are epidermal growth factor-regulated growth repressors. J Biol Chem. 1998;273:13848-13854.
43. Emery SC, Karpinski NC, Hansen L, Masliah E. Abnormalities in central nervous system development in osteogenesis imperfecta type II. Pediatr Dev Pathol. 1999;2:124-130.